Fed Circuit split over $235m skinny label verdict
The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
7th Circuit won’t overturn spinal implant injunction
The US Court of Appeals for the Seventh Circuit has upheld a preliminary injunction from an Illinois court that blocked medical device maker Aegis Spine from selling its spinal implant.
Shionogi and Duchesnay add new patents to Osphena dispute
Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
FTC urges Congress to step in over AbbVie antitrust claim
The US Federal Trade Commission has dropped its remaining claim in a lawsuit against AbbVie and Besins Healthcare, after the US Supreme Court declined to rule that consumers had a right to be compensated by the companies.
US Judiciary Committee advances four bills to curb antitrust pharma practices
The US Senate Judiciary Committee has unanimously voted to pass four bills that aim to crack down on anti-competitive practices in the pharmaceutical industry.
Is big pharma’s antidote to the COVID-19 waiver a viable alternative?
In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Bio-Rad and 10X Genomics end patent fight with new licensing deal
Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
FDA approves milestone biosimilar insulin drug
The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
New York judge denies arbitration request in $881m cannabinoid suit
A New York federal court has denied biotechnology company Amyris’ bid for arbitration in an $881 million trade secrets and patent infringement dispute with cannabis firm Lavvan.
